Pilot & Feasibility Program

飞行员

基本信息

批准号：
10608971
负责人：
ATUL K BHAN
金额：
$ 23.54万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-01-01 至 2026-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10608971
关键词：
Achievement Appointment Area Award Biology Cells Charge Chemicals Classification Clinical Research Collaborations Development Digestive System Disorders Disease Educational workshop Eligibility Determination Faculty Fostering Funding Funding Agency General Hospitals Goals Grant Growth Health Human Genetics Inflammatory Bowel Diseases Investigation Israel Journals Laboratory Research Letters Massachusetts Medical center Mission Natural Immunity Patients Peer Review Physiological Pilot Projects Postdoctoral Fellow Public Health Schools Publishing Reporting Research Research Personnel Resources Science Scientist Systems Biology Therapeutic Translational Research United States National Institutes of Health Universities adaptive immunity base clinical translation gut microbiome high risk innovation medical schools meetings member novel programs recruit success

项目摘要

PILOT AND FEASIBILITY PROGRAM: PROJECT SUMMARY Dr. Atul Bhan, Pilot and Feasibility Program Director, will evaluate letters of intent for suitability, assist the Center Director with identification of appropriate reviewers, and examine reviews received. Dr. Bhan is charged specifically with reviewing these initial funding proposals in the context of the overall programmatic goals of the Center in fostering new digestive disease investigators and advancing understanding of IBD. He will also chair the meeting of the CSIBD Executive Steering Committee that decides the ranking of proposals for funding. Dr. Kate Jeffrey will serve as the Associate Director of the Pilot and Feasibility Program. The overall goal of the CSIBD Pilot and Feasibility Program is to provide initial support for laboratory, translational, and clinical research relevant to IBD and to stimulate innovative research relevant to IBD. These goals unfold along the P and F Program’s specific aims: 1) Recruit new investigators into digestive disease research by providing funding for IBD-related nascent research programs; and 2) Generate new ideas related to IBD research by providing funding for innovative high-risk high-payoff lines of investigation. All CSIBD members are eligible to receive funding through the Pilot and Feasibility program. In addition, other investigators within MGH, Beth Israel Deaconess Medical Center, Broad Institute, Harvard Medical School, MIT, Tufts, the University of Massachusetts Medical School, and the Harvard School of Public Health may apply for support through this program. Awardees are expected to attend CSIBD seminars and workshops, interact with other Center investigators, and present their findings to the CSIBD members, in addition to formal reporting to the Executive Steering Committee. Over the past 10 years, 71% of Pilot and Feasibility Program awards have been for young investigators without current or past independent NIH support (Type N proposals), 21% have been for Type EN, and 8% have been for Type E. This ongoing priority in funding is reflected in the representative projects funded in the last four years which are included with this renewal application.

试点和可行性计划：项目摘要试点和可行性项目总监 Atul Bhan 博士将评估意向书的适用性，协助 Bhan 博士负责确定适当的评审员并检查收到的评审意见。特别是在总体规划目标的背景下审查这些初步供资提案他还将担任该中心的主席，该中心致力于培养新的消化疾病研究人员和增进对 IBD 的了解。 CSIBD 执行指导委员会会议决定资助提案的排名。凯特·杰弗里（Kate Jeffrey）将担任试点和可行性计划的副主任。 CSIBD 试点和可行性计划的总体目标是为实验室、与 IBD 相关的转化和临床研究，并刺激与 IBD 相关的创新研究。目标展示了 P 和 F 计划的具体目标：1) 招募新的消化系统疾病研究人员通过为 IBD 相关的新兴研究项目提供资金进行研究；以及 2) 产生相关的新想法；通过为创新的高风险高回报的调查线提供资金来支持 IBD 研究。所有 CSIBD 成员都有资格通过试点和可行性计划获得资金。 MGH、贝斯以色列女执事医疗中心、布罗德研究所、哈佛医学院的研究人员，麻省理工学院、塔夫茨大学、马萨诸塞大学医学院和哈佛大学公共卫生学院可能通过该计划申请支持获奖者应参加 CSIBD 研讨会和讲习班，除正式报告外，与其他中心调查员互动，并向 CSIBD 成员展示他们的发现过去 10 年，71% 的试点和可行性工作向执行指导委员会报告。项目奖项颁发给没有当前或过去独立 NIH 支持的年轻研究人员（N 型提案），21% 属于 EN 型，8% 属于 E 型。资助情况反映在过去四年资助的代表性项目中，这些项目包含在本报告中续订申请。